75 related articles for article (PubMed ID: 29433143)
1. Effects of pyrrolopyrimidine derivatives on cancer cells cultured in vitro and potential mechanism.
Kilic-Kurt Z; Celik A; Bakar-Ates F
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3169-3177. PubMed ID: 37891256
[TBL] [Abstract][Full Text] [Related]
2. Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.
Mfuh AM; Larionov OV
Curr Med Chem; 2015; 22(24):2819-57. PubMed ID: 26087764
[TBL] [Abstract][Full Text] [Related]
3. Biological properties of pyrroloquinoline and pyrroloisoquinoline derivatives.
Králová P; Soural M
Eur J Med Chem; 2024 Apr; 269():116287. PubMed ID: 38492334
[TBL] [Abstract][Full Text] [Related]
4. A scheme to underpin key mediator(s) in Salinosporamide(s) against pan-tumor via systems biology concept.
Oh KK; Yoon SJ; Song SH; Park JH; Kim JS; Kim MJ; Kim DJ; Suk KT
J Transl Med; 2024 May; 22(1):492. PubMed ID: 38789990
[No Abstract] [Full Text] [Related]
5. Coumarin-furo[2,3-
Wang T; Gao Y; Wu F; Luo L; Ma J; Hu Y
RSC Med Chem; 2024 May; 15(5):1565-1577. PubMed ID: 38784474
[TBL] [Abstract][Full Text] [Related]
6. Halogenated Pyrrolopyrimidines with Low MIC on
Olsen CE; Blindheim FH; Søgaard CK; Røst LM; Singleton AH; Bergum OET; Bruheim P; Otterlei M; Sundby E; Hoff BH
Antibiotics (Basel); 2022 Jul; 11(8):. PubMed ID: 35892374
[TBL] [Abstract][Full Text] [Related]
7. Oxidative Stress and 4-hydroxy-2-nonenal (4-HNE): Implications in the Pathogenesis and Treatment of Aging-related Diseases.
Li Y; Zhao T; Li J; Xia M; Li Y; Wang X; Liu C; Zheng T; Chen R; Kan D; Xie Y; Song J; Feng Y; Yu T; Sun P
J Immunol Res; 2022; 2022():2233906. PubMed ID: 35411309
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel pyrroles and fused pyrroles as antifungal and antibacterial agents.
Abd El-Hameed RH; Sayed AI; Mahmoud Ali S; Mosa MA; Khoder ZM; Fatahala SS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2183-2198. PubMed ID: 34602000
[TBL] [Abstract][Full Text] [Related]
9. Novel Bis- and Mono-Pyrrolo[2,3-
Bistrović Popov A; Vianelo R; Grbčić P; Sedić M; Pavelić SK; Pavelić K; Raić-Malić S
Molecules; 2021 Jun; 26(11):. PubMed ID: 34206076
[TBL] [Abstract][Full Text] [Related]
10. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Ghith A; Ismail NSM; Youssef K; Abouzid KAM
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
[TBL] [Abstract][Full Text] [Related]
11. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
[TBL] [Abstract][Full Text] [Related]
12. Pyrrole: An emerging scaffold for construction of valuable therapeutic agents.
Gholap SS
Eur J Med Chem; 2016 Mar; 110():13-31. PubMed ID: 26807541
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Drug Res (Stuttg); 2018 Sep; 68(9):485-498. PubMed ID: 29433143
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
Pathania S; Rawal RK
Eur J Med Chem; 2018 Sep; 157():503-526. PubMed ID: 30114661
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
